3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > AIDS/HIV -

Study confirms drug combo prevents AIDS

AIDS/HIVJul 29, 05

Combination treatment with anti-AIDS drugs cut the rate of progression from infection with HIV to AIDS by 86 percent compared to patients not receiving treatment, British researchers said on Friday.

They found that the effectiveness of highly active antiretroviral therapy (HAART), a combination of at least three agents from two drug classes, increased with time.

“Our results indicate that HAART reduced the rate of progression to AIDS by 86 percent and that its effectiveness compared with no treatment increased with time since initiation,” said Dr. Jonathan Sterne, of the University of Bristol, in southwestern England, who headed the research team.

But HAART was less beneficial for patients believed to be infected through intravenous drug use.

The anti-AIDS drug combinations have transformed the illness in Western countries from a death sentence to a chronic disease, but doctors have been concerned about long-term impact.

The treatments consist of drugs that interrupt the life cycle of the human immunodeficiency virus (HIV) in different ways, fighting the rapidly mutating virus on several fronts at once.

HIV destroys the immune system and leaves the body vulnerable to a variety of life-threatening diseases, including opportunistic infections, such as tuberculosis.

The scientists studied more than 3,200 patients involved in a Swiss study after January 1996 when HAART first became available in Switzerland.

They compared the impact on patients of HAART, with dual therapy and no drug treatment. The results are reported in The Lancet medical journal.

“The very large benefits of HAART that are achievable in developed countries should remind us of the urgency of providing treatment for millions of people who could benefit in other parts of the world, particularly sub-Saharan Africa,” Sterne said.

About 39 million people worldwide are living with HIV/AIDS. Sub-Saharan Africa is the worst affected region.

About 1 million of the 6 million people in poor countries who need the life-saving drugs are receiving them, according to the World Health Organisation.

It had hoped to have 3 million people on treatment by the end of 2005 but admitted in June it would not meet the target.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  Hepatitis C more prevalent than HIV/AIDS or Ebola yet lacks equal attention
  Cell-associated HIV mucosal transmission: The neglected pathway
  Offering option of initial HIV care at home increases use of ART
  HIV-1 movement across genital tract cells surprisingly enhanced by usurping antibody response
  Indonesia probes Bali tattoo HIV infection report
  Obama raises U.S. goal on fighting AIDS
  New device to test blood can spot cancer cells, HIV on the fly
  Rare HIV-positive individuals shed light on how body could effectively handle infection
  New research examines how HIV infections occur on the molecular level
  An answer to a longstanding question: How HIV infection kills T cells
  Researchers say uncover HIV, insulin resistance link
  Beatrice Hahn and George Shaw, Pioneers in HIV Research, to Join Penn Medicine

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site